176 related articles for article (PubMed ID: 19191868)
1. High expression of BCL3 in human myeloma cells is associated with increased proliferation and inferior prognosis.
Brenne AT; Fagerli UM; Shaughnessy JD; Våtsveen TK; Rø TB; Hella H; Zhan F; Barlogie B; Sundan A; Børset M; Waage A
Eur J Haematol; 2009 May; 82(5):354-63. PubMed ID: 19191868
[TBL] [Abstract][Full Text] [Related]
2. B-cell CLL/lymphoma 3 promotes glioma cell proliferation and inhibits apoptosis through the oncogenic STAT3 pathway.
Wu J; Li L; Jiang G; Zhan H; Wang N
Int J Oncol; 2016 Dec; 49(6):2471-2479. PubMed ID: 27748795
[TBL] [Abstract][Full Text] [Related]
3. The proto-oncogene Bcl3 induces immune checkpoint PD-L1 expression, mediating proliferation of ovarian cancer cells.
Zou Y; Uddin MM; Padmanabhan S; Zhu Y; Bu P; Vancura A; Vancurova I
J Biol Chem; 2018 Oct; 293(40):15483-15496. PubMed ID: 30135206
[TBL] [Abstract][Full Text] [Related]
4. BCL3 is induced by IL-6 via Stat3 binding to intronic enhancer HS4 and represses its own transcription.
Brocke-Heidrich K; Ge B; Cvijic H; Pfeifer G; Löffler D; Henze C; McKeithan TW; Horn F
Oncogene; 2006 Nov; 25(55):7297-304. PubMed ID: 16732314
[TBL] [Abstract][Full Text] [Related]
5. Impaired Bcl3 up-regulation leads to enhanced lipopolysaccharide-induced interleukin (IL)-23P19 gene expression in IL-10(-/-) mice.
Mühlbauer M; Chilton PM; Mitchell TC; Jobin C
J Biol Chem; 2008 May; 283(21):14182-9. PubMed ID: 18375954
[TBL] [Abstract][Full Text] [Related]
6. IL-3 expression by myeloma cells increases both osteoclast formation and growth of myeloma cells.
Lee JW; Chung HY; Ehrlich LA; Jelinek DF; Callander NS; Roodman GD; Choi SJ
Blood; 2004 Mar; 103(6):2308-15. PubMed ID: 14615378
[TBL] [Abstract][Full Text] [Related]
7. Bcl3: a regulator of NF-κB inducible by TWEAK in acute kidney injury with anti-inflammatory and antiapoptotic properties in tubular cells.
Poveda J; Sanz AB; Carrasco S; Ruiz-Ortega M; Cannata-Ortiz P; Sanchez-Niño MD; Ortiz A
Exp Mol Med; 2017 Jul; 49(7):e352. PubMed ID: 28684863
[TBL] [Abstract][Full Text] [Related]
8. Gene regulation by BCL3 in a cervical cancer cell line.
Maldonado V; Espinosa M; Pruefer F; Patiño N; Ceballos-Canciono G; Urzua U; Juretic N; Melendez-Zajgla J
Folia Biol (Praha); 2010; 56(4):183-93. PubMed ID: 20974051
[TBL] [Abstract][Full Text] [Related]
9. Interleukin-9 regulates NF-kappaB activity through BCL3 gene induction.
Richard M; Louahed J; Demoulin JB; Renauld JC
Blood; 1999 Jun; 93(12):4318-27. PubMed ID: 10361130
[TBL] [Abstract][Full Text] [Related]
10. High-level expression of BCL3 differentiates t(2;5)(p23;q35)-positive anaplastic large cell lymphoma from Hodgkin disease.
Nishikori M; Maesako Y; Ueda C; Kurata M; Uchiyama T; Ohno H
Blood; 2003 Apr; 101(7):2789-96. PubMed ID: 12456498
[TBL] [Abstract][Full Text] [Related]
11. C-MAF oncogene dysregulation in multiple myeloma: frequency and biological relevance.
Rasmussen T; Knudsen LM; Dahl IM; Johnsen HE
Leuk Lymphoma; 2003 Oct; 44(10):1761-6. PubMed ID: 14692531
[TBL] [Abstract][Full Text] [Related]
12. Changes in expression induced by Epstein-Barr Virus LMP1-CTAR1: potential role of bcl3.
Edwards RH; Marquitz AR; Raab-Traub N
mBio; 2015 Apr; 6(2):. PubMed ID: 25873381
[TBL] [Abstract][Full Text] [Related]
13. Expression profile of telomere-associated genes in multiple myeloma.
Díaz de la Guardia R; Catalina P; Panero J; Elosua C; Pulgarin A; López MB; Ayllón V; Ligero G; Slavutsky I; Leone PE
J Cell Mol Med; 2012 Dec; 16(12):3009-21. PubMed ID: 22947336
[TBL] [Abstract][Full Text] [Related]
14. BCL3 Reduces the Sterile Inflammatory Response in Pancreatic and Biliary Tissues.
Song L; Wörmann S; Ai J; Neuhöfer P; Lesina M; Diakopoulos KN; Ruess D; Treiber M; Witt H; Bassermann F; Halangk W; Steiner JM; Esposito I; Rosendahl J; Schmid RM; Riemann M; Algül H
Gastroenterology; 2016 Feb; 150(2):499-512.e20. PubMed ID: 26526716
[TBL] [Abstract][Full Text] [Related]
15. An integrated genomic-transcriptomic approach supports a role for the proto-oncogene BCL3 in atherosclerosis.
Marchetti G; Girelli D; Zerbinati C; Lunghi B; Friso S; Meneghetti S; Coen M; Gagliano T; Guastella G; Bochaton-Piallat ML; Pizzolo F; Mascoli F; Malerba G; Bovolenta M; Ferracin M; Olivieri O; Bernardi F; Martinelli N
Thromb Haemost; 2015 Mar; 113(3):655-63. PubMed ID: 25374339
[TBL] [Abstract][Full Text] [Related]
16. The imbalance between Survivin and Bim mediates tumour growth and correlates with poor survival in patients with multiple myeloma.
Romagnoli M; Séveno C; Wuillème-Toumi S; Amiot M; Bataille R; Minvielle S; Barillé-Nion S
Br J Haematol; 2009 Apr; 145(2):180-9. PubMed ID: 19298592
[TBL] [Abstract][Full Text] [Related]
17. Identification of c-myc promoter-binding protein and X-box binding protein 1 as interleukin-6 target genes in human multiple myeloma cells.
Wen XY; Stewart AK; Sooknanan RR; Henderson G; Hawley TS; Reimold AM; Glimcher LH; Baumann H; Malek LT; Hawley RG
Int J Oncol; 1999 Jul; 15(1):173-8. PubMed ID: 10375612
[TBL] [Abstract][Full Text] [Related]
18. Variant of BCL3 gene is strongly associated with five-year survival of non-small-cell lung cancer patients.
Dimitrakopoulos FI; Antonacopoulou AG; Kottorou A; Marousi S; Koukourikou I; Kalofonou M; Panagopoulos N; Scopa C; Dougenis D; Papadaki H; Papavassiliou AG; Kalofonos HP
Lung Cancer; 2015 Sep; 89(3):311-9. PubMed ID: 26122346
[TBL] [Abstract][Full Text] [Related]
19. Regulation of Bcl-2-family proteins in myeloma cells by three myeloma survival factors: interleukin-6, interferon-alpha and insulin-like growth factor 1.
Jourdan M; De Vos J; Mechti N; Klein B
Cell Death Differ; 2000 Dec; 7(12):1244-52. PubMed ID: 11175262
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of Bcl3 gene expression mediates the anti-proliferative action of estrogen in pituitary lactotrophs in primary culture.
Mitsui T; Ishida M; Izawa M; Kagami Y; Arita J
Mol Cell Endocrinol; 2011 Oct; 345(1-2):68-78. PubMed ID: 21787835
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
